Delestrogen Shortage: A Provider's Guide for 2026
The ongoing shortage of Delestrogen (Estradiol Valerate injection, USP) and its generic equivalents continues to impact patient care across multiple specialties. This guide provides prescribers with current supply information, evidence-based alternative recommendations, dosing conversion guidance, and strategies for managing affected patients.
Current Supply Status
As of early 2026, Estradiol Valerate injection remains subject to intermittent supply constraints nationwide. Key supply details:
- Brand (Delestrogen): Manufactured by Par Pharmaceutical (Endo International). Available in 10 mg/mL, 20 mg/mL, and 40 mg/mL concentrations in 5 mL multi-dose vials. Supply remains inconsistent.
- Generic: Perrigo and other generic manufacturers produce Estradiol Valerate injection in 20 mg/mL and 40 mg/mL concentrations. Generic availability has been somewhat more reliable than brand but still subject to spot shortages.
- ASHP status: Estradiol Valerate injection has appeared on the ASHP drug shortage list multiple times since 2016, with the most recent listings reflecting manufacturing delays and increased demand.
Root Causes
Understanding the supply dynamics helps with patient communication and clinical planning:
Limited Manufacturing Base
The injectable Estradiol Valerate market is served by a small number of manufacturers. This oligopolistic supply structure means a single production disruption (equipment failure, raw material shortage, regulatory action) can create nationwide shortages. The sterile injectable manufacturing requirements add complexity and limit new market entrants.
Demand Growth
Demand has increased substantially due to:
- Expanded access to gender-affirming hormone therapy, with injectable estrogen being the preferred route for many transgender women
- Telehealth platforms lowering barriers to HRT prescribing
- Growing clinical preference for parenteral over oral estrogen due to the favorable thrombotic risk profile of non-oral routes
- Patient advocacy driving broader insurance coverage for gender-affirming care
Regulatory and Supply Chain Factors
Post-pandemic supply chain normalization has been slow for sterile injectables. Active pharmaceutical ingredient (API) sourcing, carrier oil quality standards, and fill-finish capacity all remain potential bottleneck points.
Clinical Impact Assessment
The shortage affects several patient populations under your care:
- Menopausal patients: Those on Delestrogen for vasomotor symptoms or vulvar/vaginal atrophy may experience symptom recurrence if unable to fill prescriptions
- Hypogonadal patients: Women with primary ovarian insufficiency or surgical menopause depend on consistent estrogen replacement for bone health, cardiovascular protection, and quality of life
- Transgender patients: Interruptions in feminizing hormone therapy can cause significant psychological distress, symptom regression, and may impact patient retention in care
- Oncology patients: Rare, but patients receiving high-dose Estradiol Valerate for advanced prostate cancer may need alternative approaches
Therapeutic Alternatives and Dosing Conversions
Estradiol Cypionate (Injectable)
The most pharmacologically similar alternative. Key prescribing considerations:
- Pharmacokinetics: Longer duration of action than Estradiol Valerate; produces a lower, later, and more prolonged peak. Half-life approximately 8-10 days vs. 4-5 days for Estradiol Valerate.
- Dose conversion: Estradiol Cypionate doses are typically 20-30% lower than equivalent Estradiol Valerate doses due to slower release. For example, a patient on Estradiol Valerate 20 mg IM every 2 weeks might convert to Estradiol Cypionate 5 mg IM every 2 weeks, with subsequent titration based on serum levels.
- Availability: Brand Depo-Estradiol has been discontinued. Compounded Estradiol Cypionate is available from 503A and 503B compounding pharmacies.
- Carrier oil: Typically compounded in cottonseed or grapeseed oil (vs. sesame/castor oil for Delestrogen). Relevant for patients with oil allergies.
Transdermal Estradiol (Patches)
Consider for patients who can achieve adequate estrogen levels via this route:
- Products: Climara (weekly), Vivelle-Dot (twice weekly), generic estradiol patches
- Dose equivalence: Approximate: Climara 0.1 mg/day patch ≈ Estradiol Valerate 5-10 mg IM every 2 weeks. Titrate based on clinical response and serum levels.
- Advantages: Steady-state pharmacokinetics, avoids injection, comparable thrombotic risk profile to injectable. Good availability and insurance coverage.
- Limitations: May not achieve sufficiently high estradiol levels for some transgender patients. Skin adherence issues in some patients.
Oral Estradiol
Widely available as a bridge therapy:
- Products: Estrace (brand), generic estradiol tablets (numerous manufacturers)
- Dosing: 1-8 mg daily depending on indication. Can be taken sublingually to partially bypass first-pass hepatic metabolism.
- Thrombotic risk: Higher VTE risk than parenteral routes due to first-pass hepatic effect increasing clotting factor production. Consider this when counseling patients, particularly those with additional VTE risk factors.
- Best used as: Temporary bridge during injectable shortage, or for patients without elevated thrombotic risk
Compounded Injectable Estradiol
A viable option during shortages:
- Available from PCAB-accredited compounding pharmacies (503A pharmacies) and FDA-registered outsourcing facilities (503B)
- Can be compounded as Estradiol Valerate or Estradiol Cypionate in custom concentrations
- Verify pharmacy credentials and quality assurance practices
- Insurance coverage may be limited; discuss cost implications with patients
Patient Management Strategies
Proactive Communication
- Alert patients currently on Delestrogen about potential supply issues at their next visit
- Document a contingency plan in the medical record
- Provide patients with tools to find the medication: recommend MedFinder for Providers to help patients locate pharmacies with stock
Prescription Flexibility
- Write prescriptions for generic "Estradiol Valerate injection" rather than brand "Delestrogen" to maximize pharmacy options
- Consider prescribing multiple concentrations (e.g., if 20 mg/mL is unavailable, authorize 40 mg/mL with adjusted volume)
- Include a backup prescription for an alternative formulation that the patient can fill if their primary medication is unavailable
Monitoring During Transitions
- Check serum estradiol levels 4-8 weeks after any formulation change
- For menopausal patients: trough estradiol levels of 40-100 pg/mL are generally therapeutic
- For transgender patients on feminizing HRT: target estradiol levels per Endocrine Society guidelines (100-200 pg/mL)
- Monitor for symptom changes and adjust dosing accordingly
Reporting and Advocacy
- Report shortage impacts to the FDA Drug Shortage Staff (drugshortages@fda.hhs.gov)
- Report to ASHP drug shortage resource center
- Support institutional and professional society advocacy for manufacturing capacity expansion
Resources
%2C%20Color%3DOriginal.png)
